AIGISRx Antibacterial Envelope from TYRX Cleared by FDA

TYRX announced today that the FDA has cleared the Fully Resorbable AIGISRx R Antibacterial Envelope for use. 

Advertisement

 
The device is a mesh envelope impregnated with antimicrobial agents rifampin and minocycline designed to hold cardiovascular implanted electronic devices in place and to lower the risk of surgical site infections. 
 
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
 
The AIGISRx R Antibacterial Envelope is for use with pacemakers and implantable cardioverter defibrillators. 
 

More Articles on Quality: 

5 Time-Out Tips for Safe Surgery

9 Latest Findings on Link Between HIT, Safety, & Quality

Patient Safety Tool: Nutrition Toolkit for Healthcare Providers

 

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.